Stocks and Investing
Stocks and Investing
Thu, August 20, 2020
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Wed, August 19, 2020
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Joseph Schwartz Maintained (BMRN) at Buy with Decreased Target to $113 on, Aug 19th, 2020
Joseph Schwartz of SVB Leerink, Maintained "BioMarin Pharmaceutical Inc." (BMRN) at Buy with Decreased Target from $140 to $113 on, Aug 19th, 2020.
Joseph has made no other calls on BMRN in the last 4 months.
There are 2 other peers that have a rating on BMRN. Out of the 2 peers that are also analyzing BMRN, all agree with Joseph's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- George Farmer of "BMO Capital" Maintained at Hold with Increased Target to $108 on, Thursday, August 6th, 2020
- Matthew Harrison of "Morgan Stanley" Downgraded from Buy to Hold and Held Target at $125 on, Wednesday, July 8th, 2020